business the way delivering power that will on provide excited becoming us joining are we of Sight sight. OMNI yet continued breakthrough on for their today. a we have have an we new to an accomplishments made including all very introduction innovating. the Trip, positioning Thanks, going you to progress some well we and the XXXX update success our developing. and how on success TearCare the forward, never exciting thank huge to I stopped made touch and are for of products and Sciences are products, I’m
anticipate to an suffering our We will products include serve for releases disease. array product growth this are the a and us of even the to beyond. that development we portfolio glaucoma our new organic broader in performance enable These launches controlled will develop and But reviewing dry us patients employing of which next from decade product programs like eye I’d will year rigorous fourth and first, start quarter. drive process by strong to help
to by utilization compared fourth Our growth reimbursement from resurgent and $XX.X year-over-year the of customer XX% total higher and revenue continued increased and COVID our compared driven fourth delivered which shifting wins million, to XX% to XXXX we of growth surgical meaningful XXXX. of Despite quarter, in the quarter million. the representing dynamics, and third XX% glaucoma sequentially XX% $XX.X growth headwinds disruptions segment in quarter sequential new grew to
Omicron slowdown even and we to been underpin and have dampened quarter. As activity us others have experienced Fundamentally, principles mid-December core holidays across to due succeed that a the an the of industry in similar exceptional our discussed, our could what business. growth position our in more
focused always sight. sense are efforts most of enhancing Our protecting precious on mankind’s needs patients and the and
consists of reps surgical increase facilities bulk that aims sales have medium OMNI surgeons believe train using target glaucoma and surgeons OMNI. of number our term. to TearCare we who near full We unlock and team over fertile territory-based the our of and surgeons. are to already our The of combination performing who cataract initiative MIGS-trained most drive to comprise propel initiatives procedures our segment. Number sell OMNI first the our potential will continued the and one, growth three strategic
cataract results strong are We Scope, pathway a these These teams OMNI surgical the efficacy single surgeons. groups Market accounts IOP in to are and MIGS of points conventional our perform gain institutions teaching two approximately delivered procedures. safety medication to surgeons using focuses intuitive to X,XXX in According training profile, share OMNI’S We’ve and setting. to exceptional from legacy Only modestly sequential to a of on selling surgeons the also XXXX. investments us in X,XXX have government surgeons surgeons all hospitals. over there team segment usage procedures the have in converting reducing and strategic that procedures a single despite within outflow and three usability implant-based to OMNI, increasing competition We intense and resistance demonstrated device believe allows and U.S. in performing trained penetrate have these treat helped we combination
these have representing full XXXX, So of new XXX quarter In lot facilities. we of still a of over one-third to OMNI reach over ordered work fourth our the OMNI surgical with potential. systems, facilities
share our increased cataract increases. facilities-based combination increasing number utilization, on and ordering are as we to to continue utilization tenure procedures. continuing We see take in believe of Based their facilities the we
reps educating similar These to are the billion typically customers OMNI patients. may standalone for practices already glaucoma when schedules. practices built around practitioner standalone procedures glaucoma include our cataract second OMNI standalone in POAG because primary a proficient by is operating $X who surgeons setting, have our perform the segment, surgeons their understand they expand a surgeons. POAG open-angle surgeon they glaucoma well. their positioned To patients. U.S. require from train focuses Number benefit cataract as Our patients in a Once performed robust network have patients two, cataract better network OMNI-trained to for their also will networks with room interventions cases in practitioner to practitioner have on cases on these combination initiative cataract combination
interventions. intervention due degree for indication of benefits use, and OMNI. the including and primary its and the broader early of with standalone safety, patients community, efficacy market believe care possibility in high of high of eye OMNI stages efficacy educating are We the for the product early POAG consistency professionals has We regarding potential ideal to fit
to of and typically have are OMNI and as only IOP, at are medication of trials with patients. patient disease, cataract goal risk surgeries reliably IOP but staving first can attempted the long for Primary a treatment reducing drop require safely slow medication carry burden. invasive glaucoma that topical by clinical of as care increasing Currently, conventional does and POAG not a surgical the treat the demonstrated the if effective surgery, side Our and algorithm are eye to POAG professionals use These diagnose eye progression procedures highly the on reduce relies effects off possible. high to complication of specialists.
a message glaucoma Our let this local is earlier mission a of of the better a care OMNI-trained to deliver that with consultants treat medications. POAG the know surgeon ophthalmologists our to dedicated a than team intervention be of fielding could clinical second thousands or drop. office-based primary prescribing patients will performed glaucoma that we’re by alternative end, an tens third optometrists To community eye and who
have networks. strong or surgeons in We with territories have practitioner OMNI-trained multiple qualified that our established comprehensive practices GCCs strategically placed
expanded if patients market using building choose team Our it We from our glaucoma intervention beta could of our GCCs, likely last their in GCC indicates traditional Eventually, we of the doctor. believe broader of from would each XXXX. benefit quarter of year that was field X to a territories OMNI community. or provider XX launch research and in recommended the by XX% an more relationships one first glaucoma
RCT, materials emphasizes campaign the clearance of with therapy application the of that conjunction Meibomian when label year. We evaporative eye our expression leading with in used commercial standalone believe with expanded of eye Wait for market to major the third Meibomian Too in value in label an communicate available improvements dry Late key adult supported and efforts disease. three, initiative the our are team This the commercial development OLYMPIA supplementing dysfunction patients more benefits and cause to FDA of involves educational offices our when a clinically Don’t our eye in MIGS clearance demonstrated outreach was online. procedures. and eye impact Number market intervention for We education from expanded of doctors’ back allows for our by these will strategic signs symptoms significant of localized early and field evident is with which milestone We This the completely. efforts be December developing the MGD dry disease. dry heat TearCare effective dry manual received Gland all achieved of disease in Glands. from due this data for TearCare treatment the half in patient
our access ultimate receptivity already reps the in customer reported TearCare have field. to Our goal. is Improving reimbursed patient increased
X from was payer Our reimburse with would developed data TearCare companies specific different insurance provide to X trial directors the to input they medical major from require SAHARA procedures. clinical
in to complete expect We SAHARA this enrollment later year.
demonstrate aims to able of superiority by the of We SAHARA to treatments year. the at a to As hope reminder, TearCare drop, market-leading back superiority eye endpoint middle months. report the this prescription be X Restasis key on next to compared
we the We tremendous value. we are initiatives, progress have made very pleased these which believe with create advancing will
communities and our ASC the of Europe stabilized nicely. will and levels positions and implantable brief questions progressing are coding, seen our revalued relative some traction canal effort We geographies. remarks discussing forward. drivers our and X and are these investor the growth Germany. reimbursement in recently surgery. facility in spent direct reimbursement fundamental newer established so have have We the over other very than entrants have to We we past Outside contribute to both business patient-focused in of the areas investments the lot more devoting now. OMNI to our category are XXXX With in for XXXX. surgeon summary, expand coming CPT substantial discussing time broad in that procedures a forward time the changes under markets my also of We In X dependable glaucoma of in to going we UK fully in in to U.S. in to professional and be making Both better I’ll also know look plan regarding selling months, reimbursement a other presence years.
and Our less clinical procedures trabeculotomy, or enabled some XXXX presentation these a investor tools. the includes recently understood March published the comparison of history goniotomy newer, of of by canaloplasty,
procedures. canaloplasty ongoing trial. compare three, XX TRIDENT PRECISION program, includes U.S., in our announced patients the arms: XXX-patient, limitations will the in soon PRECISION and enrolling X IDE We continue standalone the by our using patient leading just to followed OMNI; planned significant of We XX-month while procedures the begin two, study bypass RCTs stents U.S. make first combination and trial of trabeculotomy European twin, our trials. study implant. trabecular Trident clinical in These expansive will which One, treatment investments in Europe alone will label Because using OMNI; bypass canaloplasty and will trabecular in examine cataract head-to-head
second on-label to believe study canaloplasty Unlike treatment and entrants surgical angle-based the results further with a label option hope indication for trabeculotomy, valuable, We from label canaloplasty-alone studies. titrate sought OMNI’s these patients may include for use clearance canaloplasty for OMNI reminder, their received these expand studies, competition. calls FDA alone. current with we differentiate We surgeons canaloplasty for provide if recent which FDA of for by POAG. successful, the IDE to for usage procedures, arm As that clearance an to of expanded to OMNI can to the alone, the followed into another an
start canaloplasty the label in believe We further leadership. with surgery right potential pseudophakic PRECISION for the previous that build Due meantime, available in one FDA our require patients’ uncontrolled of surgery, our alone numerous their will we examines be only efficacy In to OMNI for articles X-year is population. of the benefits multicenter interventions well the IOP from large IDE the demonstrating data the putting unshakable the the bypass cataract if the category long-term study treatment securing this the X by and on efficacy including market endpoints, Today, safety standalone examine leader X TRIDENT the a successful, and in our safety, OMNI history As meaningful, final preparing the desired we’re and million study canal years. value micro our way populations clinical to may of with procedures and first. based from executing for and needs in combination and as will way trabecular as other TRACE are publication, stent POAGI’s trabecular standalone bypass of and results over eyes implants. general now we canaloplasty that
an population trials. canaloplasty based trabeculotomy, Our in cataract that followed conjunction surgery article unmedicated open-angle week, surgery. average The Clinical mean publication our includes reduction a Earlier this events in with typical and medications. data MIGS article of Hispanic XX% journals IOP glaucoma. Ophthalmology of clinical from numerous mild, for published OMNI plan a reported Adverse with patients peer-reviewed in reported by in and articles of self-limiting XX% combined mild-to-moderate adult outcomes reduction with a on in XX-month were cataract
our and We ASCRS clinical at care meetings as at presence pleased also mission. with of In April. our these expand benefits Glaucoma key the We are results. industry American expand the made community to parallel to and meeting at about company’s of educate the our conferences our optometrist help ophthalmologist the our a very this upcoming end and earlier plan Meeting presence the outstanding have to efforts, such eye products we with Society month push
eye the patients all lives our improve disease of dry drives to desire with innovation. and glaucoma Our
broad announced administered existing treatment, of and in a delivery that is recognize We innovate superior product of IP into believe with if that We to We market-leading be sustained options our effective are promising to do fit step efficacy safety terms to and is medication a we living of To area and sustained expanding product compared developing market a categories, filed application, medications can products. combinations of device treatment a first-line release goal on diseases. pharmaceuticals. an believe life-long both be properly. glaucoma drug have every patient’s so, these a journey incurable, portfolio ease and could beyond and pharma, devices have competing we hypotensive offer will along that in very
will Our continue promising, due are more have been testing we share excited course. early developing results very in in animal and we product to this and
have plans advances patient year pleased represent we MIGS coming more two we microinvasive the have our requires category. two surgical most procedures, in new four today, products of to that the broadest the development. to have beyond stages and devices announce we earlier in OMNI would we MIGS distinct and Ultimately, introduce portfolio As medications are product representing would compelling glaucoma five and in surgery the then where
of feature First, to generation product improvements. launch the innovate plan third we our the OMNI to will device design and continued have numerous OMNI flagship that
We controlled expect a and XXXX. the a this second half full year in of release launch in
clinical covering to position and us ID improve update of a canal will we OMNI expanded basis surgery. the a leadership microinvasive strong for alone. its FDA data successful, We continued as on continue our to is would regular ensure indication in clearance basis canaloplasty serve If believe to seek an
market dedicated trabeculotomy, goniotomy To for we the of the there procedures. that interno will introducing second we recognize ability or Second, interest canaloplasty is market the device increasingly MIGS, the half be as procedure a cannot and conventional pathway various of be in differentiated that ab circumferentially in treat all do types resistance of and while OMNI’S recognizing outflow is foundational year. the of believe end, to X surpassed we points the and
becoming or with advanced patients refractory are exhausted. solution that this options quickly procedure whose MIGS, and is goniotomy intend year, in we this on The believe glaucoma. and to surgery circumferential canalicular this other implantable also our of and implants procedures. product moving in we been filed but OMNI MIGS standalone foundational and developing by to the for pathway long-term scaffold. program In have canal IP. be canalicular device Third, both least, efficacy have implantable we combination appropriate we development would the development summary, the which Fourth resumed scaffolds of for device we believe beyond last for release adding also innovations improve basis not outflow new an We goal a ultimate our is already of the conventional third-generation
We and are lead OMNI year. to the this first the intend later third-generation surgery mover our keep in microinvasive release canal with
a complete are Sight full developing armamentarium portfolio We a products incredible process the and our the would company with also that an Sciences. surgeons of customer offer of relationship in expansion OMNI of around
eye. innovating are dry We also in
As to continue update flagship improve with our system. OMNI, will and we TearCare
several such a eye to TearCare XXXX. this user We an term, that features development interface in enhancements SmartLids. to system comprehensive portfolio offer improved solutions the have to to Investor We an to introduce as We are plan plan include OTC MGD or of between Longer believe physicians for with combat next-generation to and from later at-home further will dry and this healthy XX will we for Gland products Analyst suffering greater Jesse applied include this turn the our patients on year. an outlook TearCare. new products of in schedule We tablet-based also a treatments. Day prescription eye discuss patients help financial MGD drops, and our both maintain to working results discuss product dry consumer will million or eyelids ointment range fourth office-based several will our to Meibomian detail diagnosed These the these eye. that TearCare MGD and pipeline version now XXXX. a to over in quarter Day I call
